Tesamorelin ir sint\u0113tisks pept\u012bds, kas pal\u012bdz organismam dabiski palielin\u0101t aug\u0161anas hormona (GH) ra\u017eo\u0161anu un izdal\u012b\u0161anos. Tas ir izstr\u0101d\u0101ts, lai atdarin\u0101tu aug\u0161anas hormona atbr\u012bvojo\u0161\u0101 hormona (GHRH) darb\u012bbu, kas ir dabisks smadzen\u0113s ra\u017eots hormons, kur\u0161 dod sign\u0101lu hipof\u012bzei atbr\u012bvot GH. Tesamorelin vislab\u0101k paz\u012bstams ar t\u0101 ietekmi uz viscer\u0101lo tauku audu (VAT) samazin\u0101\u0161anu, kas ir dzi\u013ci v\u0113dera tauki, kas uzkr\u0101jas ap iek\u0161\u0113jiem org\u0101niem. \u0160is tauku veids ir cie\u0161i saist\u012bts ar vielmai\u0146as probl\u0113m\u0101m un ar HIV saist\u012btu lipodistrofiju, kas ir tauku sadal\u012bjuma trauc\u0113jumi, kas rodas antiretrov\u012brusu terapijas laik\u0101.<\/p>\n
Tesamorelin darbojas, saistoties ar GHRH receptoriem hipof\u012bz\u0113. Tas stimul\u0113 organismu atbr\u012bvot savu aug\u0161anas hormonu dabiskos pulsos, kas p\u0113c tam palielina insul\u012bnam l\u012bdz\u012bg\u0101 aug\u0161anas faktora-1 (IGF-1) l\u012bmeni. IGF-1 ir hormons, kas saist\u012bts ar vielmai\u0146u, audu atjauno\u0161anos, musku\u013cu masas saglab\u0101\u0161anu un \u0161\u016bnu aug\u0161anu. At\u0161\u0137ir\u012bb\u0101 no tie\u0161iem aug\u0161anas hormona injekcij\u0101m, tesamorelin neaizst\u0101j \u0101r\u0113ju GH. T\u0101 viet\u0101 tas stimul\u0113 organisma dabisko aug\u0161anas hormona sist\u0113mu.<\/p>\n
Liel\u0101k\u0101 da\u013ca p\u0113t\u012bjumu par tesamorel\u012bnu ir v\u0113rsti uz cilv\u0113kiem, kuri dz\u012bvo ar HIV un kuriem antiretrovir\u0101l\u0101s terapijas laik\u0101 veidojas liekais v\u0113dera tauku sl\u0101nis. Kl\u012bniskie p\u0113t\u012bjumi ir atk\u0101rtoti pier\u0101d\u012bju\u0161i, ka tesamorel\u012bns var iev\u0113rojami samazin\u0101t v\u0113dera tauku audu daudzumu, viduk\u013ca apk\u0101rtm\u0113ru un tauku daudzumu \u0137erme\u0146a vidusda\u013c\u0101, vienlaikus parasti saglab\u0101jot zem\u0101das tauku audus, proti, taukus zem \u0101das, k\u0101 ar\u012b taukus rok\u0101s un k\u0101j\u0101s. Placebo kontrol\u0113tos p\u0113t\u012bjumos, kas ilga no 6 l\u012bdz 12 m\u0113ne\u0161iem, bie\u017ei tika nov\u0113rota v\u0113dera tauku samazin\u0101\u0161an\u0101s par aptuveni 10\u201318%. P\u0113tnieki nov\u0113roja ar\u012b uzlabojumus savas \u0101r\u0113j\u0101s izskata uztver\u0113 un da\u017eos metabolisk\u0101s vesel\u012bbas r\u0101d\u012bt\u0101jos. Taj\u0101 pa\u0161\u0101 laik\u0101 p\u0113t\u012bjumi par\u0101d\u012bja, ka p\u0113c tesamorel\u012bna lieto\u0161anas p\u0101rtrauk\u0161anas v\u0113dera tauki pak\u0101peniski atgriez\u0101s, kas liecina, ka efekta saglab\u0101\u0161anai var b\u016bt nepiecie\u0161ama terapijas turpin\u0101\u0161ana.<\/p>\n
Tesamorelinu p\u0113t\u012bts ar\u012b attiec\u012bb\u0101 uz t\u0101 ietekmi uz aknu taukain\u012bbu un vielmai\u0146as vesel\u012bbu. Pacientiem ar HIV saist\u012btu NAFLD (nealkoholisko taukainu aknu slim\u012bbu) p\u0113t\u012bjumos tika nov\u0113rots akn\u0101s uzkr\u0101to tauku daudzuma samazin\u0101jums, vienlaikus uzlabojoties ar aknu darb\u012bbu saist\u012btajiem vielmai\u0146as r\u0101d\u012bt\u0101jiem. Svar\u012bgi, ka \u0161ie efekti tika nov\u0113roti bez iev\u0113rojama glikozes l\u012bme\u0146a kontroles pasliktin\u0101\u0161an\u0101s. Zin\u0101tnieki ar\u012b analiz\u0113ja tesamorelinu potenci\u0101lo ietekmi uz iekaisumu, tauku vielmai\u0146u, taukaudu kvalit\u0101ti, vesel\u012bgu noveco\u0161anos un smadze\u0146u darb\u012bbu, \u0146emot v\u0113r\u0101 t\u0101 mijiedarb\u012bbu ar aug\u0161anas hormona un IGF-1 (insul\u012bna l\u012bdz\u012bg\u0101 aug\u0161anas faktora 1) ce\u013ciem, kas saist\u012bti ar atjauno\u0161anos un vielmai\u0146u.<\/p>\n
Tesamorelin tiek uzskat\u012bts par pept\u012bdu, jo tas sast\u0101v no aminosk\u0101b\u0113m, kas sak\u0101rtotas veid\u0101, kas atdarina dabisko cilv\u0113ka GHRH. T\u0101 ir modific\u0113ta un stabil\u0101ka dabisk\u0101 GHRH versija, kas izstr\u0101d\u0101ta, lai b\u016btu iztur\u012bg\u0101ka pret organisma fermentu sadal\u012b\u0161anos. Pateicoties tam, Tesamorelin saglab\u0101jas akt\u012bvs ilg\u0101k un efekt\u012bv\u0101k stimul\u0113 aug\u0161anas hormona izdal\u012b\u0161anos nek\u0101 dabiskais GHRH, vienlaikus saglab\u0101jot dabisk\u0101ku hormonu izdal\u012b\u0161an\u0101s modeli.<\/p>\n
P\u0113t\u012bjumi ar\u012b liecina, ka tesamorelin var uzlabot \u0137erme\u0146a sast\u0101vu, samazinot viscer\u0101lo tauku daudzumu, vienlaikus palielinot lies\u0101s \u0137erme\u0146a masas daudzumu. Vair\u0101ki kl\u012bniskie p\u0113t\u012bjumi un zin\u0101tniskie p\u0101rskati ir par\u0101d\u012bju\u0161i viduk\u013ca apk\u0101rtm\u0113ra, vid\u0113jo tauku daudzuma un aknu tauku samazin\u0101\u0161anos, palielinoties musku\u013cu masai un IGF-1 l\u012bmenim. \u0160\u012bs izmai\u0146as parasti tika sasniegtas bez nopietn\u0101m blakuspar\u0101d\u012bb\u0101m vai nopietniem hormon\u0101l\u0101s nel\u012bdzsvarot\u012bbas trauc\u0113jumiem, kas at\u0161\u0137ir tesamorelin no tie\u0161as aug\u0161anas hormonu terapijas.<\/p>\n
Lai gan tesamorelin galvenok\u0101rt tiek saist\u012bts ar HIV saist\u012btu lipodistrofiju, zin\u0101tnisk\u0101 interese ir papla\u0161in\u0101jusies ar\u012b uz cit\u0101m jom\u0101m, piem\u0113ram, ar aptauko\u0161anos saist\u012btiem vielmai\u0146as trauc\u0113jumiem, aknu steatozi, vesel\u012bgu noveco\u0161anos, kognit\u012bvaj\u0101m funkcij\u0101m un taukaudu biolo\u0123iju. Zin\u0101tnieki \u012bpa\u0161i interes\u0113jas par GHRH analogu ietekmi uz dzi\u013cajiem v\u0113dera taukiem, mitohondriju funkcij\u0101m, iekaisumu, metabolismu un audu atjauno\u0161an\u0101s meh\u0101nismiem.<\/p>\n
Inform\u0101cija par tesamorelinu ir tikai izgl\u012btojo\u0161a un zin\u0101tniska. Tesamorelin ir recep\u0161u z\u0101les, kas ir apstiprin\u0101ts noteiktai medic\u012bniskai lieto\u0161anai, un t\u0101 pla\u0161\u0101kas ietekmes p\u0113t\u012bjumi v\u0113l joproj\u0101m turpin\u0101s. \u0160eit aprakst\u012btie p\u0113t\u012bjumi, meh\u0101nismi un rezult\u0101ti pamatojas uz public\u0113tiem zin\u0101tniskiem datiem, un tos nedr\u012bkst uztvert k\u0101 medic\u012bnisku padomu, diagnozi vai terapeitisku ieteikumu. Person\u0101m, kas apsver hormon\u0101lu terapiju vai uz pept\u012bdiem balst\u012btas intervences, j\u0101konsult\u0113jas ar kvalific\u0113tu vesel\u012bbas apr\u016bpes speci\u0101listu.<\/p>\n
Tesamorelin darbojas, atdarinot dabisk\u0101 aug\u0161anas hormonu atbr\u012bvojo\u0161\u0101 hormona (GHRH) iedarb\u012bbu, kas ir atbild\u012bgs par sign\u0101lu p\u0101rraid\u012b\u0161anu hipof\u012bzei, lai atbr\u012bvotu aug\u0161anas hormonu (GH). P\u0113c ievad\u012b\u0161anas tesamorelin saist\u0101s ar GHRH receptoriem hipof\u012bzes \u0161\u016bn\u0101s, ko sauc par somatotropiem. Tas izraisa organisma pa\u0161a aug\u0161anas hormona atbr\u012bvo\u0161anos dabiskos pulsos. Kad GH l\u012bmenis paaugstin\u0101s, aknas s\u0101k ra\u017eot vair\u0101k insul\u012bnam l\u012bdz\u012bg\u0101 aug\u0161anas faktora-1 (IGF-1), kas ir atbild\u012bgs par daudz\u0101m ar tesamorelinu saist\u012btaj\u0101m vielmai\u0146as ietekm\u0113m un \u0137erme\u0146a sast\u0101va izmai\u0146\u0101m.<\/p>\n
Tesamorelin darb\u012bbas meh\u0101nisma vissvar\u012bg\u0101k\u0101 iez\u012bme ir t\u0101, ka tas pastiprina organisma dab\u012bgo aug\u0161anas hormona sist\u0113mu, nevis tie\u0161i aizst\u0101j aug\u0161anas hormonu. Tas ir svar\u012bgi, jo tas \u013cauj saglab\u0101t dabisko hormonu atgriezenisk\u0101s saites meh\u0101nismu. At\u0161\u0137ir\u012bb\u0101 no tie\u0161iem GH injekciju, tesamorelin saglab\u0101 aug\u0161anas hormona puls\u0113jo\u0161u izdal\u012b\u0161anos, kas noz\u012bm\u0113, ka GH tiek atbr\u012bvots ritmiskos uzliesmojumos, kas atg\u0101dina dabisko fiziolo\u0123iju.<\/p>\n
Metabolisk\u0101 l\u012bmen\u012b tesamorelin pal\u012bdz sadal\u012bt uzkr\u0101tos taukus, \u012bpa\u0161i viscer\u0101los taukus, kas atrodas dzi\u013ci v\u0113dera dobum\u0101. Aug\u0161anas hormons aktiviz\u0113 enz\u012bmus, kas iesaist\u012bti lipol\u012bz\u0113, kas ir tauku \u0161\u016bn\u0101s uzkr\u0101to triglicer\u012bdu sadal\u012b\u0161an\u0101s process. Viscer\u0101lie tauki ir \u012bpa\u0161i jut\u012bgi pret aug\u0161anas hormonu, jo tajos ir daudz uz GH rea\u0123\u0113jo\u0161u receptoru un tiem ir augsta metabolisk\u0101 aktivit\u0101te. T\u0101p\u0113c tesamorelin galvenok\u0101rt iedarbojas uz dzi\u013cajiem v\u0113dera taukiem, vienlaikus bie\u017ei vien saglab\u0101jot zem\u0101das taukus. Kl\u012bniskie p\u0113t\u012bjumi konsekventi ir par\u0101d\u012bju\u0161i viscer\u0101lo tauku, viduk\u013ca apk\u0101rtm\u0113ra un rumpja tauku samazin\u0101\u0161anos tesamorelin terapijas laik\u0101.<\/p>\n
N\u0101kam\u0101 svar\u012bg\u0101 tesamorelinas darb\u012bbas sast\u0101vda\u013ca ir IGF-1 l\u012bme\u0146a paaugstin\u0101\u0161an\u0101s. \u0160o hormonu galvenok\u0101rt ra\u017eo aknas, ko stimul\u0113 aug\u0161anas hormons, un tas pal\u012bdz uztur\u0113t musku\u013cu masu, veicina audu atjauno\u0161anos, olbaltumvielu sint\u0113zi un vielmai\u0146u. Augst\u0101ks IGF-1 l\u012bmenis ir saist\u012bts ar palielin\u0101tu lies\u0101s \u0137erme\u0146a masas apjomu, uzlabotiem atjauno\u0161an\u0101s procesiem un lab\u0101ku \u0161\u016bnu atjauno\u0161anos. Da\u017ei p\u0113t\u012bjumi ar\u012b liecina, ka IGF-1 var\u0113tu atbalst\u012bt smadze\u0146u vesel\u012bbu, mitohondriju darb\u012bbu, pretiekaisuma signaliz\u0101ciju un nervu \u0161\u016bnu aizsardz\u012bbu, t\u0101p\u0113c tesamorelin ir izrais\u012bjis interesi noveco\u0161an\u0101s un kognit\u012bvo funkciju p\u0113t\u012bjumos.<\/p>\n
Tesamorelin var ar\u012b uzlabot aknu vesel\u012bbu un tauku metabolismu. P\u0113t\u012bjumos par ar HIV saist\u012btu aknu aptauko\u0161anos tesamorelin samazin\u0101ja akn\u0101s uzkr\u0101to tauku daudzumu. Zin\u0101tnieki uzskata, ka tas var\u0113tu b\u016bt saist\u012bts ar vair\u0101kiem meh\u0101nismiem, tostarp palielin\u0101tu tauku sadeg\u0161anu, samazin\u0101tu jaunu tauku veido\u0161anos akn\u0101s, tauku sadal\u012bjuma uzlabo\u0161anos organism\u0101 un tauksk\u0101bju transporta ierobe\u017eo\u0161anu no taukaudiem uz akn\u0101m.<\/p>\n
N\u0101kam\u0101 b\u016btisk\u0101 ietekme attiecas uz iekaisumu un taukaudu kvalit\u0101ti. V\u0113dera tauku p\u0101rbag\u0101t\u012bba ir cie\u0161i saist\u012bta ar zems\u0101rmes hronisku iekaisumu, insul\u012bna rezistenci un vielmai\u0146as trauc\u0113jumiem. Samazinot v\u0113dera tauku daudzumu, tesamorelin var netie\u0161i uzlabot iekaisuma un vielmai\u0146as r\u0101d\u012bt\u0101jus. Da\u017ei p\u0113t\u012bjumi terapijas laik\u0101 ir nov\u0113roju\u0161i triglicer\u012bdu, adiponekt\u012bna un citu vielmai\u0146as r\u0101d\u012bt\u0101ju l\u012bme\u0146a uzlabo\u0161anos.<\/p>\n
Tesamorelin tika p\u0113t\u012bts ar\u012b iesp\u0113jam\u0101s ietekmes uz smadze\u0146u darb\u012bbu d\u0113\u013c, jo aug\u0161anas hormons un IGF-1 ietekm\u0113 daudzus neirolo\u0123iskos procesus. IGF-1 var \u0161\u0137\u0113rsot asins-smadze\u0146u barjeru un piedal\u0101s jaunu neironu veido\u0161an\u0101, nervu \u0161\u016bnu izdz\u012bvo\u0161anas atbalst\u012b\u0161an\u0101, komunik\u0101cijas uzlabo\u0161an\u0101 starp neironiem un oksidat\u012bv\u0101 stresa mazin\u0101\u0161an\u0101. Zin\u0101tnieki analiz\u0113ja, vai v\u0113dera tauku samazin\u0101\u0161ana un IGF-1 palielin\u0101\u0161ana var uzlabot kognit\u012bv\u0101s funkcijas HIV saist\u012btu neirokognit\u012bvu trauc\u0113jumu gad\u012bjum\u0101. Lai gan da\u017ei p\u0113t\u012bjumi par\u0101d\u012bja IGF-1 l\u012bme\u0146a paaugstin\u0101\u0161anos un viduk\u013ca apk\u0101rtm\u0113ra samazin\u0101\u0161anos, kognit\u012bvo funkciju uzlabo\u0161an\u0101s parasti bija m\u0113rena un ne vienm\u0113r sasniedza statistisko noz\u012bm\u012bgumu.<\/p>\n
No z\u0101\u013cu dizaina viedok\u013ca tesamorelin tika izveidots k\u0101 stabiliz\u0113ta GHRH versija. Dab\u012bgais GHRH organism\u0101 \u013coti \u0101tri sadal\u0101s, kas ierobe\u017eo t\u0101 lieto\u0161anu. Tesamorelin ietver struktur\u0101las izmai\u0146as, kas palielina t\u0101 iztur\u012bbu pret enz\u012bmu sadal\u012b\u0161anos, t\u0101d\u0113j\u0101di tas ilg\u0101k saglab\u0101jas akt\u012bvs un efekt\u012bv\u0101k stimul\u0113 aug\u0161anas hormona izdal\u012b\u0161anos p\u0113c subkut\u0101nas injekcijas.<\/p>\n
Kopum\u0101 tesamorelin darbojas k\u0101 m\u0113r\u0137tiec\u012bgs pept\u012bds, kas pastiprina organisma dab\u012bgo aug\u0161anas hormona sist\u0113mu. T\u0101 ietekme ietver aug\u0161anas hormona signaliz\u0101ciju, IGF-1 ra\u017eo\u0161anu, viscer\u0101lo tauku metabolismu, aknu tauku regul\u0101ciju un audu atjauno\u0161an\u0101s ce\u013cus. \u0160is darb\u012bbu kopums izskaidro, k\u0101p\u0113c tesamorelin ir pla\u0161i p\u0113t\u012bts viscer\u0101lo tauku, ar HIV saist\u012btas lipodistrofijas, aknu aptauko\u0161an\u0101s, vielmai\u0146as trauc\u0113jumu un citu ar nepareizu tauku sadal\u012bjumu saist\u012btu probl\u0113mu \u0101rst\u0113\u0161an\u0101.<\/p>\n
\u0160is tesamorelinas darb\u012bbas meh\u0101nisma skaidrojums ir tikai izgl\u012btojo\u0161s un zin\u0101tnisks. Lai gan kl\u012bniskie un pirmskl\u012bniskie p\u0113t\u012bjumi ir analiz\u0113ju\u0161i tesamorelinas ietekmi uz aug\u0161anas hormona signaliz\u0101ciju, metabolismu, aknu vesel\u012bbu un \u0137erme\u0146a sast\u0101vu, t\u0101 ilgtermi\u0146a dro\u0161\u012bbas un pla\u0161\u0101kas ietekmes izp\u0113te joproj\u0101m turpin\u0101s. \u0160is saturs nav medic\u012bnisks padoms un neaizst\u0101j konsult\u0101ciju ar licenc\u0113tu vesel\u012bbas apr\u016bpes speci\u0101listu.<\/p>\n
Tesamorel\u012bns ir sint\u0113tisks pept\u012bds, kas pal\u012bdz organismam dabiski pal\u012bdz\u0113t palielin\u0101t aug\u0161anas hormona (GH) ra\u017eo\u0161anu un izdal\u012b\u0161anos. Tas ir izstr\u0101d\u0101ts t\u0101, lai atdarin\u0101tu aug\u0161anas hormonu atbr\u012bvojo\u0161\u0101 hormona (GHRH) darb\u012bbu,...<\/p>","protected":false},"author":7908,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[236],"tags":[],"class_list":["post-47928","post","type-post","status-publish","format-standard","hentry","category-kategoria-tesamorelin","beh-no-thumb"],"_links":{"self":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/47928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/users\/7908"}],"replies":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/comments?post=47928"}],"version-history":[{"count":0,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/posts\/47928\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/media?parent=47928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/categories?post=47928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioevidencehub.com\/lv\/wp-json\/wp\/v2\/tags?post=47928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}